Propensity score matching as an effective strategy for biomarker cohort design and omics data analysis
PLOS ONE · 02.05.2024 · 19 (5) · e0302109
DOI: 10.1371/journal.pone.0302109 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 02.05.2024. Verfasst von Masaki Maekawa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, United States of America. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Colorectal Neoplasms, Propensity Score. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, Neuroendocrine Tumor Research Foundation.
Abstract (Originalsprache)
Background
Analysis of omics data that contain multidimensional biological and clinical information can be complex and make it difficult to deduce significance of specific biomarker factors.
Methods
We explored the utility of propensity score matching (PSM), a statistical technique for minimizing confounding factors and simplifying the examination of specific factors. We tested two datasets generated from cohorts of colorectal cancer (CRC) patients, one comprised of immunohistochemical analysis of 12 protein markers in 544 CRC tissues and another consisting of RNA-seq profiles of 163 CRC cases. We examined the efficiency of PSM by comparing pre- and post-PSM analytical results.
Results
Unlike conventional analysis which typically compares randomized cohorts of cancer and normal tissues, PSM enabled direct comparison between patient characteristics uncovering new prognostic biomarkers. By creating optimally matched groups to minimize confounding effects, our study demonstrates that PSM enables robust extraction of significant biomarkers while requiring fewer cancer cases and smaller overall patient cohorts.
Conclusion
PSM may emerge as an efficient and cost-effective strategy for multiomic data analysis and clinical trial design for biomarker discovery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, United States of America.
- Harvard Medical School, Boston, MA, United States of America.
- Memorial Sloan Kettering Cancer Center, New York, NY, United States of America.
ORCID-Profile: Michael H Roehrl
Förderung
- NCI NIH HHS
- National Cancer Institute
- Neuroendocrine Tumor Research Foundation
Zitieren
APA
Maekawa, M., Tanaka, A., Ogawa, M., & Roehrl, M. H. (2024). Propensity score matching as an effective strategy for biomarker cohort design and omics data analysis. PLOS ONE, 19(5), e0302109. https://doi.org/10.1371/journal.pone.0302109
Vancouver
Maekawa M, Tanaka A, Ogawa M, Roehrl MH. Propensity score matching as an effective strategy for biomarker cohort design and omics data analysis. PLOS ONE. 2024;19(5):e0302109. doi:10.1371/journal.pone.0302109
BibTeX
@article{Maekawa2024,
author = {Maekawa, Masaki and Tanaka, Atsushi and Ogawa, Makiko and Roehrl, Michael H},
title = {Propensity score matching as an effective strategy for biomarker cohort design and omics data analysis},
journal = {PLOS ONE},
year = {2024},
volume = {19},
number = {5},
pages = {e0302109},
doi = {10.1371/journal.pone.0302109}
}
EUVIMED